Klotrix is one of the most effective potassium chloride supplements made by the pharmaceutical company named APOTHECON one of the group companies of Bristol-Myers Squibb Co. Klotrix has Potassium Chloride Salts as its active chemical and the drug was first approved by the Food and Drug Administration FDA of the United States precisely on the 22nd of May in the year 1980.

Registered and branded drug Klotrix is made available in the solid oral dose form of Potassium Chloride which contains 750mg of potassium chloride USP grade which is equivalent to 10 mEq of potassium, in the film-coated wax-matrix tablet. Klotrix is proposed to provide the restricted discharge of potassium from the matrix to diminish the chances of developing higher localized concentrations of potassium within the gastrointestinal tract. Klotrix is the electrolyte refilling agent. KCl is the structural formula and chemical name of potassium chloride.

Klotrix contains several inactive ingredients like Ethyl-cellulose, FD&C Yellow No.6 Aluminum Lake color, Glycerin, Hydroxy-propyl methyl-cellulose 2910, Magnesium Stearate, Povidone, Colloidal Silicon Dioxide, Stearic Acid and Titanium Dioxide. The clinical pharmacology of Klotrix involves: the potassium ion is the vital intracellular cation (positively charged ions) majority of the body tissues that participate in several significant physiological processes that incorporate the maintenance of intracellular tonicity, the communication of nerve impulses, the contraction of cardiac, skeletal, and smooth muscles as well as maintaining the normal renal functions.

The drug is indicated for use that it should be reserved for the patients who cannot tolerate or not willing to take liquids or fizzy potassium preparations or for patients having certain problems of complying with such preparations merely due to the reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride formulations.